
You are here
Consultations
We conduct public consultations as part of our broader stakeholder engagement work, including on changes to regulatory requirements or practices, reviews of business processes, standards or guidelines, and TGA fees and charges.
Filters
Status
Categories
- Advertising (2) Apply Advertising filter
- Australian Register of Therapeutic Goods (ARTG) (1) Apply Australian Register of Therapeutic Goods (ARTG) filter
- Remove Biologicals filter Biologicals (2)
- Complementary medicines (7) Apply Complementary medicines filter
- Fees/Payments (1) Apply Fees/Payments filter
- Import/Export (1) Apply Import/Export filter
- Remove Labelling/Packaging filter Labelling/Packaging (1)
- Remove Legislation filter Legislation (3)
- Listed medicines (2) Apply Listed medicines filter
- Medical devices/IVDs (55) Apply Medical devices/IVDs filter
- Remove Medical devices safety filter Medical devices safety (1)
- Remove Medicinal cannabis filter Medicinal cannabis (0)
- Medicines (2) Apply Medicines filter
- Medicines safety (1) Apply Medicines safety filter
- Remove OTC medicines filter OTC medicines (12)
- Other therapeutic goods (1) Apply Other therapeutic goods filter
- Prescription medicines (5) Apply Prescription medicines filter
- Scheduling (55) Apply Scheduling filter
- Therapeutic Goods Administration (TGA) (2) Apply Therapeutic Goods Administration (TGA) filter
- Therapeutic goods regulation (2) Apply Therapeutic goods regulation filter
- (-) Remove Biologicals filter Biologicals
- (-) Remove OTC medicines filter OTC medicines
- (-) Remove Medical devices safety filter Medical devices safety
- (-) Remove Medicinal cannabis filter Medicinal cannabis
- (-) Remove Legislation filter Legislation
- (-) Remove Labelling/Packaging filter Labelling/Packaging
Priority Review pathway for biologicals: feasibility, potential eligibility criteria and determination process
Closed on 28 March 2022
Consultation on potential regulatory options for 'export only' biologicals
Closed on 20 December 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Melatonin
Closed on 17 September 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Triptans
Closed on 17 September 2021
Proposed changes to Required Advisory Statements for Medicine Labels (RASML): Mometasone
Closed on 17 September 2021
Proposed minor changes to Required Advisory Statements for Medicine Labels (RASML): Chlorhexidine, hydrocortisone, ibuprofen
Closed on 17 September 2021
Remaking of standards and legislative instruments for human cell and tissue (HCT) products, blood and blood components
Closed on 11 July 2021
Proposed improvements to the Therapeutic Goods Advertising Code
Closed on 18 June 2021